{"generic":"Agalsidase Beta","drugs":["Agalsidase Beta","Fabrazyme"],"mono":{"0":{"id":"927743-s-0","title":"Generic Names","mono":"Agalsidase Beta"},"1":{"id":"927743-s-1","title":"Dosing and Indications","sub":{"0":{"id":"927743-s-1-4","title":"Adult Dosing","mono":"<b>Fabry's disease:<\/b> 1 mg\/kg IV infusion every 2 weeks "},"1":{"id":"927743-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>safety and effectiveness not established in pediatric patients under 8 years of age<\/li><li><b>Fabry's disease:<\/b> 1 mg\/kg IV infusion every 2 weeks<\/li><\/ul>"},"3":{"id":"927743-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Fabry's disease<br\/>"}}},"3":{"id":"927743-s-3","title":"Contraindications\/Warnings","sub":[{"id":"927743-s-3-9","title":"Contraindications","mono":"allergic to agalsidase beta or any components of the product<br\/>"},{"id":"927743-s-3-10","title":"Precautions","mono":"<ul><li>febrile patients (exacerbation)<\/li><li>compromised cardiac function (higher risk of severe complication from infusion reactions)<\/li><li>prior sensitivity to agalsidase alfa<\/li><li>renal impairment (not adequately studied)<\/li><\/ul>"},{"id":"927743-s-3-11","title":"Pregnancy Category","mono":"B (FDA)<br\/>"},{"id":"927743-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"927743-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Hypertension (10%), Hypotension (14%), Tight chest<\/li><li><b>Dermatologic:<\/b>Pruritus, Urticaria<\/li><li><b>Gastrointestinal:<\/b>Nausea (28%)<\/li><li><b>Immunologic:<\/b>Antibody development, Anti-agalsidase beta (89%), Complication of infusion, Fever (48%)<\/li><li><b>Musculoskeletal:<\/b>Arthritis\/arthrosis (10%), Musculoskeletal pain (21%), Myalgia<\/li><li><b>Neurologic:<\/b>Headache (45%), Rigor (52%)<\/li><li><b>Psychiatric:<\/b>Anxiety (28%), Depression (10%)<\/li><li><b>Respiratory:<\/b>Dyspnea, Pharyngitis (28%), Rhinitis (38%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Cardiac arrest, Cardiomegaly<\/li><li><b>Neurologic:<\/b>Cerebrovascular accident<\/li><\/ul>"},"6":{"id":"927743-s-6","title":"Drug Name Info","sub":{"0":{"id":"927743-s-6-17","title":"US Trade Names","mono":"Fabrazyme<br\/>"},"2":{"id":"927743-s-6-19","title":"Class","mono":"<ul><li>Endocrine-Metabolic Agent<\/li><li>Enzyme<\/li><\/ul>"},"3":{"id":"927743-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"927743-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"927743-s-7","title":"Mechanism Of Action","mono":"Systemic: Agalsidase catalyzes the hydrolysis of glycosphingolipids including GL-3, and provides an exogenous source of alpha-galactosidase A in Fabry disease patients.<br\/>"},"8":{"id":"927743-s-8","title":"Pharmacokinetics","sub":{"4":{"id":"927743-s-8-27","title":"Elimination Half Life","mono":"Systemic: 45 to 102 min <br\/>"}}},"9":{"id":"927743-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>for IV infusion only<\/li><li>bring to room temperature prior to reconstitution<\/li><li>reconstitute with Sterile Water for Injection; slowly inject 7.2 mL for each 35-milligram (mg) vial or 1.1 mL for each 5-mg vial down the inside wall of each vial; do NOT shake vial, roll and tilt gently; do NOT use filter needles during preparation of infusion<\/li><li>slowly withdraw the reconstituted agalsidase beta solution (5 mg\/mL) from  each vial up to the total volume required for the patient's dose; do not inject in the airspace within the  infusion bag.<\/li><li>dilute with 0.9%  NS to a minimum total volume of 50 mL for a patient weighing 35 kg or less, 100 mL for a patient weighing 35.1 to 70 kg, 250 mL for a patient weighing 70.1 to 100 kg, and 500 mL for a patient weighing more than 100 kg; before adding the required volume of reconstituted agalsidase beta solution, remove an equal volume of 0.9% NS from the infusion bag<\/li><li>avoid vigorous shaking, gently invert infusion bag to mix solution<\/li><li>may administer through in-line low protein-binding 0.2 micron filter<\/li><li>initial infusion 15 mg\/hr; subsequent infusions increase in increments of 3 to 5 mg\/hr as tolerated; in patients who weigh less than 30 kg the infusion rate should not surpass 0.25 mg\/min (15 mg\/hr); for individuals who weigh 30 kg or more, the duration of infusion should be at least 1.5 hr long<\/li><\/ul>"},"10":{"id":"927743-s-10","title":"Monitoring","mono":"<ul><li>symptomatic improvement<\/li><li>vital signs during administration<\/li><li>cardiac function<\/li><\/ul>"},"11":{"id":"927743-s-11","title":"How Supplied","mono":"<b>Fabrazyme<\/b><br\/>Intravenous Powder for Solution: 5 MG, 35 MG<br\/>"},"13":{"id":"927743-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause nausea, fever, arthritis\/arthrosis, musculoskeletal pain, headache, rigor, anxiety, depression, dyspnea, pharyngitis, and rhinitis.<\/li><li>Instruct patient to report signs\/symptoms of hypotension, cardiovascular dysfunction, or cerebrovascular accident.<\/li><li>Advise patient to call healthcare professional if a treatment is missed, as drug should be given on a regular schedule.<\/li><\/ul>"}}}